Results 221 to 230 of about 52,189 (266)
Some of the next articles are maybe not open access.
Current Research in Translational Medicine
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko +9 more
openaire +2 more sources
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko +9 more
openaire +2 more sources
CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
2021ENGELS BORIS, GUIMARAES CARLA PATRICIA
openaire +4 more sources
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
Molecular Therapy, 2023Martin Pule +2 more
exaly